期刊文献+

不同钼靶X线阳性标准对乳腺癌筛查成本效果的影响 被引量:12

Effect of Mammography-Positive Criteria on the Cost-Effectiveness of Breast Cancer Screening
下载PDF
导出
摘要 目的:根据乳腺癌筛查数据,比较不同钼靶X线阳性判定标准对其筛查成本效果的影响,为国家制定乳腺癌筛查方案提供参考。方法:在2008年7月到2009年9月,对天津、南昌、肥城和沈阳4个城市开展了一个横断面多中心的乳腺癌筛查研究项目。其中21 986例45~69岁年龄组的妇女进行了乳腺钼靶X线检查,经过1年随访,最后65例乳腺癌新发病例被确诊。根据不同钼靶X线检查阳性判定标准计算其各自的灵敏度和特异度。利用马尔科夫模型模拟整个筛查过程,计算各自的成本效果比值并对其进行敏感性分析。模拟筛查过程时,对其进行了3%的折扣。成本效果比值用挽救每个生命年所花的费用来表示,即:$/LYs(life years saved)。结果:将BIRADS分级0级(需进一步影像检查或与前次影像资料比较才能得出结论)归为阴性,筛查出55例乳腺癌,灵敏度为84.6%,特异度为98.6%,成本效果比值为45 632$/LYs;若0级为阳性,筛查出56例乳腺癌,灵敏度为86.2%,特异度为93.9%,成本效果比值为52 392$/LYs。结论:不同的钼靶X线阳性判定标准对其灵敏度影响较小,对特异度和成本效果影响较大。 Objective: The current work aims to investigate the effect of mammography-positive criteria on the cost-effectiveness of a breast cancer screening program, and provide a reference for the development of breast cancer screening programs in China. Methods: From July 2008 to September 2009, a cross-sectional breast cancer screening research project was developed in four cities: (a) Shenyang, located in northeast China; (b) Tianjin, situated in the coastal area of northern China; (c) Feicheng, an inland city in Shan- dong; and (d) Nanchang, located in southern China. A total of 21,986 asymptomatic women, aged 45 to 69 years, volunteered to under- go breast mammography examination after signing an informed consent form. After a one-year follow-up, 65 new cases with breast can- cer were diagnosed. The sensitivity and specificity of mammography were calculated on the basis of different criteria of positivity. A Markov model was used to simulate the entire screening process and calculate the cost-effectiveness ratios. The sensitivity analysis was performed using Tree Age pro 2011. The cost-effectiveness analysis was measured by the cost per life year saved ( LYs ), and the discounted rate was 3 %. Results: When the defined BIRADS 0 scale ( used for fiarther imaging scan or for comparison with the previ- ous image data to draw conclusions ) was classified as negative. A total of 55 new cases with breast cancer were detected. The sensitivity was 84.6 %, the specificity was 98.6 %, and the cost-effectiveness ratio was 45 632 ¥ / Lys. Moreover, when the defined BIRADS 0 was classified as positive, 56 new cases with breast cancer were identified, with a sensitivity of 86.2 %, a specificity of 93.9 %, and a cost-effectiveness ratio of 52 392 ¥ / LYs. Conclusion: This study suggests that different marnmography-positive criteria have minimal effect on sensitivity, but a considerable effect on specificity and cost-effectiveness.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2012年第6期328-330,339,共4页 Chinese Journal of Clinical Oncology
基金 卫生部卫生行业科研专项(编号:200902002-6) 中国工程院咨询项目(编号:2009-XY-19) 天津市科技支撑计划重点项目(编号:09ZCZDSF04800)资助 Science and Technology Foundation Supporting Program of Tianjin Health Bureau(No.2010KZ69)~~
关键词 钼靶X线检查 乳腺癌筛查 成本效果 Mammography Breast cancer screening Cost-effectiveness
  • 相关文献

参考文献15

  • 1Ferlay J,Bray F,Pisani P.Parkin DM.GLOBOCAN 2002:Cancer,Incidence,Mortality and Prevalence Worldwide[M].Lyon:IARC Cancer Base,2004:5.
  • 2Song F,He M,Li H,et al.A cancer incidence survey in Tianjin:the third largest city in China-between 1981 and 2000.Cancer Causes Control[J],2008,19(5):443-450.
  • 3Neeser K,Szucs T,Bulliard JL,et al.Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective:quantitative assessment of the most influential factors[J].Value Health,2007,10(1):42-53.
  • 4Nystrom L,Andersson I,Bjurstam N,et al.Long-term effects of mammography screening:updated overview of the Swedish ran-domised trials[J].Lancet,2002,359(9310):909-919.
  • 5George B,Harris A,Mitchell A.Cost-effectiveness analysis and the consistency of decision making:evidence from pharmaceutical reim-bursement in Australia (1991 to 1996)[J].Pharmacoeconomics,2001,19(11):1103-1109.
  • 6Plans P,Casademont L,Salleras L.Cost-effectiveness of breast cancer screening in Spain[J].Int J Technol Assess Health Care,1996,12(1):146-150.
  • 7Siegel JE,Torrance GW,Russell LB,et al.Guidelines for pharma-coeconomic studies.Recommendations from the panel on cost effec-tiveness in health and medicine.Panel on cost Effectiveness in Health and Medicine[J].Pharmacoeconomics,1997,11(2):159-168.
  • 8Wong IOL,Kuntz KM,Cowling BJ,et al.Cost effectiveness of mammography screening for Chinese women[J].Cancer,2007,110(4):885-895.
  • 9Kim K,Zang R,Choi SC,et al.Current status of gynecological cancer in China[J].J Gynecol Oncol,2009,20(2):72-76.
  • 10Yang L,Parkin DM,Ferlay J,et al.Estimates of cancer incidence in China for 2000 and projections for 2005[J].Cancer Epidemiol Bio-markers Prev,2005,14(1):243–250.

同被引文献143

引证文献12

二级引证文献315

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部